Abiomed (NASDAQ: ABMD) is a pioneer and global leader in healthcare technology and innovation, with a mission of RECOVERING HEARTS AND SAVING LIVES. Abiomed CEO, Chairman, and President, Michael R. Minogue, has focused the company’s efforts on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.
Type
Public
HQ
Danvers, US
Size (employees)
908 (est)
ABIOMED is headquartered in Danvers, US
Report incorrect company information

ABIOMED Office Locations

ABIOMED has offices in Danvers and Aachen
Danvers, US (HQ)
22 Cherry Hill Dr
Aachen, DE
3 Neuenhofer Weg
Show all (2)
Report incorrect company information

ABIOMED Financials and Metrics

ABIOMED Financials

ABIOMED's revenue was reported to be $593.75 m in FY, 2018
USD

Revenue (FY, 2018)

593.7 m

Gross profit (FY, 2018)

495.2 m

Gross profit margin (FY, 2018), %

83.4%

Net income (FY, 2018)

112.2 m

EBIT (FY, 2018)

157.1 m

Market capitalization (22-Jun-2018)

19 b

Closing share price (22-Jun-2018)

427.3

Cash (31-Mar-2018)

43 m
ABIOMED's current market capitalization is $19 b.
Annual
USDFY, 2014FY, 2015Y, 2016FY, 2017FY, 2018

Revenue

183.6 m230.3 m329.5 m445.3 m593.7 m

Revenue growth, %

25%43%35%

Cost of goods sold

98.6 m

Gross profit

495.2 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

44.3 m46.2 m48.8 m51.9 m62 m73.4 m76.4 m85.8 m103 m103 m114.7 m132.5 m132.8 m

General and administrative expense

26.2 m24.4 m31.6 m29.5 m30.1 m37.3 m39.8 m41.9 m51 m53.1 m53.9 m60.6 m60.1 m

R&D expense

7.7 m7.8 m9.1 m8.7 m8.4 m10.2 m11.6 m13.8 m15.7 m18.1 m16.3 m16.9 m19.4 m

Operating expense total

42.9 m41.6 m50.3 m47.8 m48.3 m58.4 m63.5 m68.4 m81.8 m88.4 m89.3 m99.4 m101.1 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

20.9 m22.4 m48.2 m39 m43 m

Accounts Receivable

24.4 m31.8 m42.8 m54.1 m70 m

Inventories

13.9 m16.8 m26.7 m34.9 m50.2 m

Current Assets

118 m220.1 m288.4 m327 m494.3 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

10.1 m22.6 m34.7 m17.5 m19.5 m40.4 m54.4 m53.2 m38.3 m54.7 m61.1 m44 m44.5 m

Accounts Receivable

21.1 m23 m22.8 m23.1 m28.4 m34.4 m37.1 m36.8 m41.3 m46.6 m50.2 m53.6 m57.3 m

Inventories

15.6 m14.8 m13.9 m13.4 m15.4 m21.2 m23 m25.5 m29.1 m31.5 m32.1 m36.9 m40.6 m

Current Assets

110.6 m119.7 m127.2 m135.3 m160.6 m244.1 m265.4 m281.7 m300.3 m319.9 m333.4 m350.9 m370.2 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

7.4 m113.7 m38.1 m52.1 m112.2 m

Depreciation and Amortization

2.8 m3.3 m6.2 m11 m

Inventories

(622 k)(7 m)(11 m)(12.3 m)(15.7 m)

Accounts Payable

(54 k)3.4 m(2.6 m)7.6 m4.4 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(664 k)3.7 m(1.7 m)3.8 m12.7 m8.9 m7.7 m10.6 m12.9 m8.9 m15.4 m

Depreciation and Amortization

1.3 m1.9 m

Inventories

(876 k)(69 k)13.9 m13.4 m15.4 m21.2 m23 m25.5 m29.1 m31.5 m32.1 m

Accounts Payable

(1.5 m)(1.7 m)6.8 m7.6 m8.2 m8.6 m8.8 m8.8 m8.4 m14.1 m14.6 m
USDY, 2018

Revenue/Employee

653.9 k

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

ABIOMED Online and Social Media Presence

Embed Graph
Report incorrect company information